Literature DB >> 30693535

Quantitative natural history characterization in a cohort of 142 published cases of patients with galactosialidosis-A cross-sectional study.

Tomáš Sláma1,2, Sven F Garbade3, Stefan Kölker3, Georg F Hoffmann3, Markus Ries3.   

Abstract

Galactosialidosis (GS; OMIM #256540) is a rare multisystemic inborn glycoprotein storage disease caused by biallelic mutations in the cathepsin A gene resulting in combined deficiency of the lysosomal enzymes β-galactosidase and α-neuraminidase. The precise understanding of the natural course of the disease is limited. Development of enzyme replacement therapy is at the preclinical stage. The purpose of this research project was to quantitatively characterize the natural history of the condition. Quantitative analysis of all published cases in the literature with sufficient data (N = 142 patients) was carried out. Main outcome variables were survival, diagnostic delay, description of symptoms, biomarker-phenotype associations, and radiological findings. STROBE criteria were respected. Median survival age of the cohort was 48 years. Median age of onset was 4.25 years with interquartile range (IQR) 1 to 16 years. Median age at diagnosis was 19 (IQR: 8.92-29) years, with median diagnostic delay of 8 (IQR: 4-12) years. Patients with residual β-galactosidase activity of more than 8.6% (leukocytes) survived significantly longer than patients with lower enzyme activities.
© 2018 SSIEM.

Entities:  

Keywords:  drug development; galactosialidosis; orphan disease; radiological findings; survival

Mesh:

Substances:

Year:  2019        PMID: 30693535     DOI: 10.1002/jimd.12010

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  4 in total

1.  Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein.

Authors:  Yuto Horii; Toshiki Iniwa; Masayoshi Onitsuka; Jun Tsukimoto; Yuki Tanaka; Hironobu Ike; Yuri Fukushi; Haruna Ando; Yoshie Takeuchi; So-Ichiro Nishioka; Daisuke Tsuji; Mariko Ikuo; Naoshi Yamazaki; Yoshiharu Takiguchi; Naozumi Ishimaru; Kohji Itoh
Journal:  Mol Ther Methods Clin Dev       Date:  2022-04-15       Impact factor: 5.849

2.  Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study.

Authors:  Huda B Al-Kouatly; Laura Felder; Mona M Makhamreh; Stephanie L Kass; Neeta L Vora; Vincenzo Berghella; Seth Berger; David A Wenger; Paola Luzi
Journal:  Prenat Diagn       Date:  2020-03-20       Impact factor: 3.050

3.  Quantitative analysis of the natural history of prolidase deficiency: description of 17 families and systematic review of published cases.

Authors:  Francis Rossignol; Marvid S Duarte Moreno; Carlos R Ferreira; Manuel Schiff; Jean-François Benoist; Manfred Boehm; Emmanuelle Bourrat; Aline Cano; Brigitte Chabrol; Claudine Cosson; José Luís Dapena Díaz; Arthur D'Harlingue; David Dimmock; Alexandra F Freeman; María Tallón García; Cheryl Garganta; Tobias Goerge; Sara S Halbach; Jan de Laffolie; Christina T Lam; Ludovic Martin; Esmeralda Martins; Andrea Meinhardt; Isabelle Melki; Amanda K Ombrello; Noémie Pérez; Dulce Quelhas; Anna Scott; Anne M Slavotinek; Ana Rita Soares; Sarah L Stein; Kira Süßmuth; Jenny Thies
Journal:  Genet Med       Date:  2021-05-26       Impact factor: 8.822

4.  FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.

Authors:  Sven F Garbade; Matthias Zielonka; Konstantin Mechler; Stefan Kölker; Georg F Hoffmann; Christian Staufner; Eugen Mengel; Markus Ries
Journal:  PLoS One       Date:  2020-04-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.